Background {#Sec1}
==========

Although many drugs are used in the clinical setting, these drugs may cause unexpected side effects, including effects on immunity. For example, metformin, a drug prescribed for diabetes, activates CD8+ T cells \[[@CR1]\]. Additionally, statins are hyperlipidemic drugs that have been reported to suppress immunity \[[@CR2]--[@CR5]\], and calcium channel blockers (CCBs) are antihypertensive drugs (AHTs) that have also been reported to suppress the functions of T cells and macrophages \[[@CR6]--[@CR12]\].

Immune responses around tumors are complex and can affect the therapeutic effects of chemotherapy and prognosis. Tumor-infiltrating lymphocytes (TILs), as indicators of the tumor microenvironment, affect the growth of cancer and the effects of chemotherapy. Therefore, a higher density of TILs can lead to greater therapeutic effects and improved prognoses, as has been observed in melanomas and lung cancer \[[@CR13]--[@CR15]\]. Similar results have been observed in breast cancer, particularly in triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-enriched breast cancer (HER2BC) \[[@CR16], [@CR17]\]. Therefore, we hypothesized that CCBs may reduce the TIL density, thereby disrupting the therapeutic effects of drugs and worsening prognosis.

Accordingly, in this study, we evaluated TILs before pre-operative chemotherapy (POC) in patients with breast cancer and retrospectively analyzed the correlations between CCBs and TILs or prognosis.

Methods {#Sec2}
=======

Patient background {#Sec3}
------------------

All patients who visited the Osaka City University Hospital from February 2007 to March 2018 were screened to obtain their medical histories. In cases of suspected breast cancer, core needle biopsy or vacuum-assisted biopsy was performed with ultrasonography (US). When diagnosed pathologically with breast cancer, the subtype of breast cancer was determined by immunostaining and staging with computed tomography (CT), US, and bone scintigraphy. If evaluation of metastasis to lymph nodes was difficult using these imaging tests, lymph node biopsy was performed. For immunostaining of samples, the expression levels of estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67 were evaluated. The cut-off value for Ki-67 staining was set at 15% \[[@CR18]\]. We defined ER−/PgR−/HER2+ breast cancer as HER2BC, ER−/PgR−/HER2- breast cancer as TNBC, and breast cancer that was not HER2BC or TNBC as luminal breast cancer (luminal BC) \[[@CR19]\]. In total, 338 patients with breast cancer, diagnosed with stage IIA (T1, N1, M0 or T2, N0, M0), IIB (T2, N1, M0 or T3, N0, M0), IIIA (T1--2, N2, M0 or T3, N1--2, M0), IIIB (T4, N0--2, M0), or IIIC (T1--4, N3, M0), received POC. During the first half of the POC regimen, all patients received four courses of FEC100 (500 mg/m^2^ fluorouracil, 100 mg/m^2^ epirubicin, and 500 mg/m^2^ cyclophosphamide) every 3 weeks. During the second half of the POC regimen, 12 courses of 80 mg/m^2^ paclitaxel were administered to all patients weekly, and weekly (2 mg/kg) or tri-weekly (6 mg/kg) trastuzumab was also administered in cases of HER2-positive disease \[[@CR20]--[@CR22]\]. Antitumor effects were evaluated according to the Response Evaluation Criteria in Solid Tumors \[[@CR23]\]. For analysis of the objective response rate (ORR), clinical partial response and complete response were defined as responders, and clinical stable disease and clinical progressive disease were defined as nonresponders. After confirming the therapeutic effects of POC, all patients were examined for continuation of AHTs before surgery; patients then underwent mastectomy or breast-conserving surgery \[[@CR22]\]. Pathological complete response (pCR) was defined by the National Surgical Adjuvant Breast and Bowel Project B-18 protocol as "the complete disappearance of the invasive components of the lesion with or without intraductal components, including that in the lymph nodes" \[[@CR24]\]. Standard postoperative radiotherapy was enforced if necessary, and postoperative adjuvant therapy suitable for the patient's specific subtype was performed. As follow-up after surgery, all patients had physical examinations every 3 months, US every 6 months, and CT and bone scintigraphy annually. The median follow-up time was 1287 days (range, 13--3675 days) from operation.

Histopathological evaluation of TIL density {#Sec4}
-------------------------------------------

Biopsy specimens before POC were used to evaluate TIL density. The definition and evaluation method of TILs were in accordance with the International TILs Working Group 2014 \[[@CR25]\]. The average density of the infiltrating lymphocytes within the tumor stroma in five randomly selected fields was calculated. After categorization into four classes according to the TIL density (3: \> 50%, 2: \> 10--50%, 1: ≤ 10%, or 0: absent; Additional file [1](#MOESM1){ref-type="media"}: Figure S1), scores of 2 and 3 were defined as high, and scores of 0 and 1 were defined as low \[[@CR26]\].

Ethics statement {#Sec5}
----------------

This study was conducted at Osaka City University Graduate School of Medicine, Osaka, Japan, according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines and following a retrospectively written research, pathological evaluation, and statistical plan \[[@CR27]\]. The study protocol was approved by the Ethics Committee of Osaka City University. Written informed consent was obtained from all patients (\#926).

Statistical methods {#Sec6}
-------------------

Correlations between the two groups were examined using chi-squared tests (or Fisher's exact tests when necessary). Analysis of prognosis, such as disease free survival (DFS) or overall survival (OS), was carried out using the Kaplan-Meier method and log-rank tests. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox proportional hazards model, and multivariable analysis was analyzed in the Cox regression model. Statistical significance was assumed when the *p* values were less than 0.05. The JMP 11 software program (SAS, Tokyo, Japan) was used to analyze the data.

Results {#Sec7}
=======

Clinicopathological features and differences according to subtype {#Sec8}
-----------------------------------------------------------------

Three hundred thirty-eight patients received POC; the details of their clinicopathological features are summarized in Table [1](#Tab1){ref-type="table"}. All patients were women, and the median age at operation was 55 years old (24--78 years old). The median tumor size was 28.7 mm (9.2--119.8 mm); the tumor size of 56 patients (16.6%) was 20 mm or less, and that of 44 patients (13.0%) was larger than 50 mm. Skin infiltration was observed in 50 patients (14.8%), and 224 patients (66.3%) were diagnosed with breast cancer having lymph node metastasis by imaging diagnosis. In classification by intrinsic subtype, 155 patients (45.9%) were classified as having luminal BC, 78 patients (23.1%) were classified as having HER2BC, and 105 patients (31.1%) were classified as having TNBC. Moreover, 298 patients (88.2%) were evaluated as responders in ORR. In the pathological examination of surgical specimens, 116 patients (34.3%) showed pCR. By evaluating the biopsy specimens before POC, 158 patients (46.7%) were classified into the high TIL density group, and 180 patients (53.3%) were classified in the low TIL density group.Table 1Clinicopathological features of 338 patients who were treated with preoperative chemotherapyParameters (*n* = 338)Number of patients (%)Age (years old)55 (24--78)Tumor size (mm)28.7 (9.2--119.8)Skin infiltration Negative / Positive288 (85.2%) / 50 (14.8%)Lymph node metastasis N0 / N1 / N2 / N3114 (33.7%) / 128 (37.9%) / 63 (18.6%) / 33(9.8%)Estrogen receptor Negative / Positive187 (55.3%) / 151 (44.7%)Progesterone receptor Negative / Positive236 (69.8%) / 102 (30.2%)HER2 Negative / Positive214 (63.3%) / 124 (36.7%)Ki67 ≤ 15% / \> 15%105 (31.1%) / 233 (68.9%)Intrinsic subtype Luminal BC / HER2BC / TNBC155 (45.8%) / 78 (23.1%) / 105 (31.1%)Objective response rate Non-Responders / Responders40 (11.8%) / 298 (88.2%)Pathological response Non-pCR / pCR222 (65.7%) / 116 (34.3%)TILs Low / High180 (53.3%) / 158 (46.7%)Hypertension No / Yes273 (80.8%) / 65 (19.2%)Number of medicine types for hypertension 0 / 1 / 2 / 3273 (80.8%) / 41 (12.1%) / 21 (6.2%) / 2 (0.6%) / 1 (0.3%)Calcium channel blockers No / Yes297 (87.9%) / 41 (12.1%)ACEi or ARBs No / Yes305 (90.2%) / 33 (9.8%)Beta-blockers No / Yes326 (96.4%) / 12 (3.6%)Diuretics No / Yes331 (97.9%) / 7 (2.1%)*HER* human epidermal growth factor receptor, *Luminal BC* luminal breast cancer, *HER2BC* human epidermal growth factor receptor 2-enriched breast cancer, *TNBC* triple-negative breast cancer, *pCR* pathological complete response, *TILs* tumor- infiltrating lymphocytes, *AHT* antihypertensive drug, *ACEi* angiotensin-converting-enzyme inhibitors, *ARBs* angiotensin II receptor blockers

Before POC, 65 patients (19.2%) took AHTs. Patients who had been treated before the first visit but were not treated before POC were divided into groups excluding hypertensive patients. There were no untreated patients with hypertension before POC. The following AHTs were administered: CCBs, angiotensin-converting-enzyme inhibitor, angiotensin II receptor blockers, beta-blockers, and diuretics. Forty-one patients (12.1%) were taking CCBs, and CCBs were the most commonly used medication for hypertension. Twenty-four patients (7.1%) took several medications for hypertension. No patients started new AHTs or needed additional AHTs during POC. In three patients (0.9%), AHTs were discontinued during POC. Both of these patients were taking CCBs only, and the times of discontinuation were 1.5 months, 1 month, and 10 days before surgery, respectively.

Comparison of clinicopathological features based on intrinsic subtypes showed poorer pathological response in luminal BC than in HER2BC or TNBC (luminal BC: 18.1%, HER2BC: 55.1%, TNBC: 42.9%; Additional file [2](#MOESM2){ref-type="media"}: Table S1). For age, we set the median as the cutoff value. In luminal BC, the rate of patients in the high TIL density group was lower than those in patients with other subtypes (luminal BC: 30.3%, HER2BC: 67.9%, TNBC: 55.2%). There were no significant differences in other items by subtype.

Differences in clinicopathological features due to TILs or hypertension treatment {#Sec9}
---------------------------------------------------------------------------------

We examined differences in clinicopathological features due to TILs (Additional file [3](#MOESM3){ref-type="media"}: Table S2). In the high TIL density group (*n* = 338), the expression levels of ER and PgR were significantly lower (*p* \< 0.001 and *p* \< 0.001, respectively), whereas the expression levels of HER2 and Ki67 were significantly higher than in the low TIL density group (*p* = 0.023, *p* \< 0.001, respectively). Moreover, the TIL density was significantly lower in luminal BC and significantly higher in HER2BC and TNBC (*p* \< 0.001, *p* \< 0.001, *p* \< 0.001, respectively). The ORR and pCR were significantly higher in the high TIL density group than in the low TIL density group (*p* \< 0.001, *p* \< 0.001, respectively). In 105 patients with TNBC and 78 patients with HER2BC, the same correlation between TILs and ORR or pCR was found (TNBC: *p* = 0.008, *p* = 0.042; HER2BC: *p* = 0.017, *p* = 0.019, respectively).

Notably, patients administered CCBs had significantly lower TIL densities (*p* = 0.040). Furthermore, in patients with TNBC, the TIL density was significantly lower in patients receiving hypertension treatment and patients receiving CCBs (*p* = 0.003, *p* = 0.009, respectively). In HER2BC, there were no correlations between AHTs and TILs.

The correlations between CCBs and clinicopathological features were examined in chi-squared tests and are shown in Table [2](#Tab2){ref-type="table"}. In all patients and in patients with TNBC, patients administered CCBs were significantly older than patients without CCB administration (*p* \< 0.001, *p* = 0.004, respectively). Moreover, patients with TNBC who were administered CCBs showed significantly lower response rates for POC (*p* = 0.040). No correlations between CCBs and pCRs was observed (*p* = 0.649). However, when we focused on patients with hypertension only, no relationship was found between CCBs and TILs (Additional file [4](#MOESM4){ref-type="media"}: Table S3).Table 2Difference in clinicopathological features due to calcium channel blockers^a^ParametersAll case (*n* = 338)TNBC (*n* = 105)HER2BC (*n* = 78)Calcium channel blockers*p* valueCalcium channel blockers*p* valueCalcium channel blockers*p* valueNo (*n* = 297)Yes (*n* = 41)No (*n* = 94)Yes (*n* = 11)No (*n* = 68)Yes (*n* = 10)Age (years old) ≤ 55170 (57.2%)7 (17.1%)\< 0.00159 (62.8%)2 (18.2%)0.00427 (39.7%)2 (20.0%)0.234 \> 55127 (42.8%)34 (82.9%)35 (37.2%)9 (81.8%)41 (60.3%)8 (80.0%)Tumor size (mm) ≤ 50258 (86.9%)36 (87.8%)0.86882 (87.2%)8 (72.7%)0.19760 (88.2%)10 (100.0%)0.258 \> 5039 (13.1%)5 (12.2%)12 (12.8%)3 (27.3%)8 (11.8%)0 (0.0%)Skin infiltration Negative255 (85.9%)33 (80.5%)0.36586 (91.5%)8 (72.7%)0.05558 (85.3%)9 (90.0%)0.694 Positive42 (14.1%)8 (19.5%)8 (8.5%)3 (27.3%)10 (14.7%)1 (10.0%)Lymph node status Negative102 (34.3%)12 (29.3%)0.88728 (29.8%)4 (36.4%)0.65828 (41.2%)4 (40.0%)0.945 Positive195 (65.7%)29 (70.7%)66 (70.2%)7 (63.6%)40 (58.8%)6 (60.0%)Estrogen receptor Negative166 (55.9%)21 (51.2%)------------ Positive131 (44.1%)20 (48.8%)0.574--------Progesterone receptor Negative207 (69.7%)29 (70.7%)0.893------------ Positive90 (30.3%)12 (29.3%)--------HER2 Negative190 (64.0%)24 (58.5%)0.500---------- Positive107 (36.0%)17 (41.5%)--------Ki67 ≤ 15%87 (29.3%)18 (43.9%)0.05816 (17.0%)2 (18.2%)0.92415 (22.1%)5 (50.0%)0.060 \> 15%210 (70.7%)23 (56.1%)78 (83.0%)9 (81.8%)53 (77.9%)5 (50.0%)Intrinsic subtype Luminal BC HER2BC, TNBC162 (54.5%)21 51.2%)0.690---------- Luminal BC135 (45.5%)20 (48.8%)--------Intrinsic subtype HER2BC Luminal BC, TNBC229 (77.1%)31 (75.6%)0.832---------- HER2BC68 (22.9%)10 (24.4%)--------Intrinsic subtype TNBC Luminal BC, HER2BC203 (68.4%)30 (73.2%)0.5332---------- TNBC94 (31.6%)11 (26.8%)--------Objective response rate Non-Responders32 (10.8%)8 (19.5%)0.10512 (12.8%)4 (36.4%)0.0405 (7.4%)0 (0.0%)0.382 Responders265 (89.2%)33 (80.5%)82 (87.2%)7 (63.6%)63 (92.6%)10 (100.0%)Pathological response Non-pCR195 (65.7%)27 (65.9%)0.98053 (56.4%)7 (63.6%)0.64933 (48.5%)2 (20.0%)0.093 pCR102 (34.3%)14 (34.1%)41 (43.6%)4 (36.4%)35 (51.5%)8 (80.0%)TILs Low152 (51.2%)28 (68.3%)0.04038 (40.4%)9 (81.8%)0.00922 (32.4%)3 (30.0%)0.884 High145 (48.8%)13 (31.7%)56 (59.6%)2 (18.2%)46 (67.6%)7 (70.0%)Hypertension No273 (91.9%)0 (0.0%)\< 0.00190 (95.7%)0 (0.0%)\< 0.00160 (88.2%)0 (0.0%)\< 0.001 Yes24 (8.1%)41 (100.0%)4 (4.3%)11 (100.0%)8 (11.8%)10 (100.0%)Multiple types of AHT No293 (98.6%)21 (51.2%)\< 0.00193 (98.9%)6 (54.5%)\< 0.00167 (98.5%)4 (40.0%)\< 0.001 Yes4 (1.4%)20 (48.8%)1 (1.1%)5 (45.5%)1 (1.5%)6 (60.0%)ACEi or ARBs No281 (94.6%)24 (58.5%)\< 0.00191 (96.8%)8 (72.7%)0.00162 (91.2%)4 (40.0%)\< 0.001 Yes16 (5.4%)17 (41.5%)3 (3.2%)3 (27.3%)6 (8.8%)6 (60.0%)Beta-blockers No289 (97.3%)37 (90.2%)0.02293 (98.9%)3 (27.3%)\< 0.00166 (97.1%)10 (100.0%)0.589 Yes8 (2.7%)4 (9.8%)1 (1.1%)8 (72.7%)2 (2.9%)0 (0.0%)Diuretics No293 (98.6%)38 (92.7%)0.01293 (98.9%)10 (90.9%)0.06667 (98.5%)10 (100.0%)0.704 Yes4 (1.4%)3 (7.3%)1 (1.1%)1 (9.1%)1 (1.5%)0 (0.0%)*HER* human epidermal growth factor receptor, *Luminal BC* luminal breast cancer, *HER2BC* human epidermal growth factor receptor 2-enriched breast cancer, *TNBC* triple-negative breast cancer, *pCR* pathological complete response, *TILs* tumor- infiltrating lymphocytes, *AHT* antihypertensive drug, *ACEi* angiotensin-converting-enzyme inhibitors, *ARBs* angiotensin II receptor blockers^a^Correlations between the two groups were examined in chi-squared tests

Influence of CCBs on DFS and OS {#Sec10}
-------------------------------

In all patients receiving POC, no significant differences in DFS or OS were observed due to the use of CCBs, as determined using the Kaplan-Meier method and log-rank tests (*p* = 0.712, *p* = 0.478, log-rank tests, respectively; Fig. [1](#Fig1){ref-type="fig"}a, b). Furthermore, no significant differences were found, even in patients with TNBC (DFS: *p* = 0.441, OS: *p* = 0.727, log-ranks, respectively; Fig. [1](#Fig1){ref-type="fig"}c, d).Fig. 1Comparison of disease-free survival (DFS) and overall survival (OS) using the Kaplan-Meier method based on the presence or absence of calcium channel blockers (CCBs). DFS (**a**) and OS (**b**). DFS (**c**) and OS (**d**) in patients with triple-negative breast cancer (TNBC)

In patients with TNBC, a high TIL density significantly contributed to longer DFS using univariate analysis (*p* = 0.004, HR = 0.306; Table [3](#Tab3){ref-type="table"}). Additionally, in multivariate analysis with DFS and OS, response in ORR was an independent factor (DFS: *p* = 0.004, HR = 0.258; OS: *p* = 0.001, HR = 0.143; Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Despite these results, there were no significant differences in univariate analysis with DFS or OS due to CCBs (DFS: *p* = 0.472, HR = 1.601; OS: *p* = 0.715, HR = 0.699). Similar analyses were carried out for all breast cancer and HER2BC, but no significant differences were found (Additional file [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"}, [7](#MOESM7){ref-type="media"}, [8](#MOESM8){ref-type="media"}: Table S4--7).Table 3Univariate and multivariate analysis with respect to DFS in TNBCParametersUnivarite analysisMultivariate analysisHazard ratio95% CI*p* valueHazard ratio95% CI*p* valueAge at opetation (yr) ≤ 55 vs \> 550.7580.320--1.6820.501Tumor size (mm) ≤ 50 vs \> 502.7181.056--6.2450.0391.2640.464--3.1650.630Skin infiltration Negative vs Positive2.3490.781--5.8060.118Lymph node status Negative vs Positive2.6640.922--11.2610.0731.9540.634--8.5220.263Ki67 ≤ 15% vs \> 15%1.7000.587--7.1970.359Objective response rate Non-Responders vs Responders0.1460.065--0.342\< 0.0010.2580.106--0.6380.004Pathological response Non-pCR vs pCR0.2070.060--0.5450.0010.3950.108--1.1660.095TILs Low vs High0.3060.125--0.6890.0040.4640.180--1.1200.088Hypertension No vs Yes2.2120.735--5.4760.145Multiple types of AHT No vs Yes1.3090.210--4.4310.725Calcium channel blockers No vs Yes1.6010.379--4.6270.472ACEi or ARBs No vs Yes1.5540.249--5.2650.574Beta-blockers No vs Yes0.8940.050--4.2290.911Diuretics No vs Yes2.8500.159--13.5510.378*DFS* Disease-free survival, *TNBC* triple-negative breast cancer, *CI* confidence intervals, *pCR* pathological complete response, *TILs* tumor- infiltrating lymphocytes, *AHT* antihypertensive drug, *ACEi* angiotensin-converting-enzyme inhibitors, *ARBs* angiotensin II receptor blockersTable 4Univariate and multivariate analysis with respect to OS in TNBCParametersUnivarite analysisMultivariate analysisHazard ratio95% CI*p* valueHazard ratio95% CI*p* valueAge at opetation (yr) ≤ 55 vs \> 550.5810.182--1.6030.302Tumor size (mm) ≤ 50 vs \> 502.3660.661--6.8000.168Skin infiltration Negative vs Positive2.9480.822--8.4880.0913.3210.891--10.3070.071Lymph node status Negative vs Positive2.2690.631--14.4740.233Ki67 ≤ 15% vs \> 15%3.7620.756--68.1810.120Objective response rate Non-Responders vs Responders0.0900.032--0.244\< 0.0010.1430.045--0.4300.001Pathological response Non-pCR vs pCR0.0740.004--0.365\< 0.0010.1430.008--0.7990.024TILs Low vs High0.4110.140--1.1090.0790.9030.288--2.6540.855Hypertension No vs Yes1.1610.182--4.1810.847Multiple types of AHT No vs Yes0.9280.051--4.6090.942Calcium channel blockers No vs Yes0.6990.039--3.4650.715ACEi or ARBs No vs Yes1.1610.064--5.7590.887Beta-blockers No vs Yes----0.206Diuretics No vs Yes4.1380.228--20.6310.258*OS* Overall survival, *TNBC* triple-negative breast cancer, *CI* confidence intervals, *pCR* pathological complete response, *TILs* tumor- infiltrating lymphocytes, *AHT* antihypertensive drug, *ACEi* angiotensin-converting-enzyme inhibitors, *ARBs* angiotensin II receptor blockers

Discussion {#Sec11}
==========

In previous studies, CCBs have been shown to inhibit apoptosis by interfering with calcium-triggered signals, suggesting the possibility of promoting cancer \[[@CR28]\]. Accordingly, numerous studies have been conducted on the risk of developing breast cancer by CCBs \[[@CR29], [@CR30]\]. A recent meta-analysis of observational studies has reported that there is no correlation between CCBs and carcinogenesis in breast cancer (risk ratio: 1.07, 95% CI: 0.99--1.16) \[[@CR29]\]. In contrast, some reports have shown that CCBs suppress the activity of T cells by inhibiting interleukin-2, which is required for the differentiation of T cells \[[@CR6], [@CR8], [@CR9], [@CR31]\].

In this study, we evaluated the correlations of TILs with hypertension and AHTs and showed, for the first time, that the TIL density was decreased by CCBs. This result suggested that CCBs may also affect the immune TME (iTME). In particular, in patients with TNBC, responders in ORR decreased as the TIL density decreased, consistent with our hypothesis. Nonetheless, CCBs did not affect prognosis. We speculated that this result could be related to changes in the ratios of TIL subsets. TILs contain various subsets, some of which suppress the growth of cancer, and some of which promote cancer progression \[[@CR25]\]. In one study, the concentration of CCBs that suppressed T cells differed depending on the T-cell type; CD4-positive T cells were suppressed at lower CCB concentrations than CD8-positive T cells \[[@CR7]\]. Additionally, many reports have shown that increased numbers of CD8-positive T cells in the iTME are an indicator of improved prognosis \[[@CR32], [@CR33]\]. In contrast, other reports have shown that increased numbers of CD4-positive T cells in the iTME can be related to either an improved or worsened prognosis \[[@CR32], [@CR34], [@CR35]\]. The poor prognosis could be explained by the observation that CD4 is expressed in most regulatory T cells that promote cancer progression. We have previously reported that the CD8 to FOXP3 lymphocyte ratio in the iTME affects the therapeutic outcomes and prognosis of patients with TNBC and HER2BC who received POC \[[@CR36]\]. However, the strength of the inhibitory effect on T cells varies depending on the type of CCB \[[@CR9]\]. Furthermore, macrophages also play a major role in the iTME and are suppressed by CCBs \[[@CR10], [@CR31], [@CR37]\]. In this study, we did not analyze the type and dose of CCBs; thus, these drugs may have affected the ratio of TIL subsets and thereby influenced prognosis.

This study was limited by the fa13ct that we did not evaluate the different types and doses of AHTs used. Moreover, it was not known when or for how long patients were taking AHTs before POC. In other words, changes over time due to CCBs were unclear. After operation, it is unknown how treatment for hypertension was performed. However, our data strongly supported that CCBs influenced the iTME. Depending on the method for using CCBs, iTME may be exacerbated, which may lead to a poor prognosis. In contrast, if our hypothesis is correct and we can further suppress TILs that promote cancer by adjusting CCBs, we may be able to improve prognoses. Indeed, we previously reported that the iTME affects prognosis after recurrence \[[@CR38]\]. Therefore, in future studies, we plan to evaluate changes in the iTME during treatment and assess the influence of CCBs on iTME.

Conclusions {#Sec12}
===========

In patients with TNBC undergoing treatment with CCBs for hypertension, TILs in the needle biopsy specimens before treatment were significantly lower, and the response rate of POC was not effective. These results suggested that immunosuppressive action by CCBs may affect not only lymphocytes in the blood but also lymphocytes in the immune microenvironment.

Additional files
================

 {#Sec13}

Additional file 1:**Figure S1.** Histopathological evaluation of TILs. TIL density was evaluated in biopsy specimens by core needle biopsy or vacuum-assisted biopsy taken before pre-operative chemotherapy. Five random fields were evaluated. (A) \> 50%: score 3, (B) \> 10--50%: score 2, (C) ≤ 10%: score 1, (D) absent: score 0. (PPTX 2000 kb) Additional file 2:**Table S1.** Clinicopathological features by subtype. (DOCX 21 kb) Additional file 3:**Table S2.** Difference in clinicopathological features due to TILs. (DOCX 24 kb) Additional file 4:**Table S3.** Difference in clinicopathological features due to calcium channel blockers in hypertension patients. (DOCX 25 kb) Additional file 5:**Table S4.** Univariate and multivariate analysis with respect to DFS. (DOCX 22 kb) Additional file 6:**Table S5.** Univariate and multivariate analysis with respect to DFS in HER2BC. (DOCX 21 kb) Additional file 7:**Table S6.** Univariate and multivariate analysis with respect to OS. (DOCX 22 kb) Additional file 8:**Table S7.** Univariate and multivariate analysis with respect to OS in HER2BC. (DOCX 21 kb)

AHTs

:   Antihypertensive drugs

CCBs

:   Calcium channel blockers

CIs

:   Confidence intervals

CT

:   Computed tomography

DFS

:   Disease-free survival

ER

:   Estrogen receptor

HER2

:   Human epidermal growth factor receptor 2

HER2BC

:   Human epidermal growth factor receptor 2-enriched breast cancer

HR

:   Hazard ratio

iTME

:   Immune tumor microenvironment

Luminal BC

:   Hormone receptor-positive breast cancer

ORR

:   Objective response rate

OS

:   Overall survival

pCR

:   Pathological complete response

PgR

:   Progesterone receptor

POC

:   Pre-operative chemotherapy

REMARK

:   Reporting Recommendations for Tumor Marker Prognostic Studies

TILs

:   Tumor-infiltrating lymphocytes

TNBC

:   Triple-negative breast cancer

US

:   Ultrasonography

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

We thank Yayoi Matsukiyo and Tomomi Okawa (Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine) for helpful advice regarding data management.

All authors were involved in the preparation of this manuscript. KTakada collected the data, and wrote the manuscript. SK, YA, WG, KTakahashi and TT performed the operation and designed the study. KTakada, SK and ST summarized the data and revised the manuscript. HF, KH and MO substantial contribution to the study design, performed the operation, and revised the manuscript. All authors read and approved the final manuscript.

This study was funded by grants from the Japan Society for the Promotion of Science (KAKENHI, Nos. 25461992, 26461957, and 17 K10559) to Shinichiro Kashiwagi. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

The data and materials used and analyzed in the current study would be available from the corresponding author on request.

Written informed consent was obtained from all subjects. This research conformed to the provisions of the Declaration of Helsinki in 2013. All patients were informed of the investigational nature of this study and provided their written, informed consent. The study protocol was approved by the Ethics Committee of Osaka City University (\#926).

Not applicable

The authors declare that they have no competing interests.
